Activating Compound | Comment | Organism | Structure |
---|---|---|---|
interleukin-13 | treatment of tracheal tissue is associated with an early activation of phosphoinositide 3-kinase | Mus musculus |
Protein Variants | Comment | Organism |
---|---|---|
D910A | site-directed mutagenesis of isoform p110delta, catalytically inactive. Interleukin is unable to induce hyper-responsiveness in tissues expressing the mutant | Mus musculus |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | i.e. LY294002, treatment prevents interleukin-13-induced hyper-responsiveness | Mus musculus | |
2-(6-aminopurin-9-ylmethyl)-5-methyl-3-O-tolyl-3H-quinazolin-4-one | i.e.IC87114, selective for isoform p110delta. Treatment prevents interleukin-13-induced hyper-responsiveness | Mus musculus | |
Wortmannin | treatment prevents interleukin-13-induced hyper-responsiveness | Mus musculus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
smooth muscle | tracheal smooth muscle | Mus musculus | - |